Abstract

PreScription: Shortages Continue--Compounding Pharmacies Fill the Gap…Again!

Author(s): Allen Loyd V Jr

Issue: May/Jun 2023 - Volume 27, Number 3

View All Articles in Issue

Page(s): 180

Download in electronic PDF format for $75

Abstract

Related Keywords

Related Categories

Printer-Friendly Version

Related Articles from IJPC

Issue/Page View/Buy	Title/Author (Click for Abstract / Details / Purchase)
May/Jun 2023 Pg. 180	PreScription: Shortages Continue--Compounding Pharmacies Fill the Gap…Again! Author(s): Allen Loyd V Jr
Jul/Aug 2016 Pg. 351 View Sample	Discrepancies in the Law and the U.S. Food and Drug Administration Pharmacy Compounding Compliance Policy Guidelines Author(s): Allen Loyd V Jr
Mar/Apr 2022 Pg. 100-109	Allowing Compounding Pharmacies to Address Drug Shortages Author(s): Broughel James
Mar/Apr 2023 Pg. 92	PreScription: Amoxicillin Shortage Continues: Compounding Pharmacies Filling the Gap! Author(s): Allen Loyd V Jr
Sep/Oct 2017 Pg. 356	PreScription: 2017 Pharmacy Compounding Issues: The U.S. Food and Drug Administration, Harzardous Drugs, and Wasted Drugs Author(s): Allen Loyd V Jr
Nov/Dec 2015 Pg. 487-488	U.S. Food and Drug Administration "Evaluation Criteria" for Difficult to Compound Drugs Author(s): Allen Loyd V Jr
Jul/Aug 2015 Pg. 303-305	U.S. Food and Drug Administration Proposed Guidance Document: Compounding Animal Drugs from Bulk Substances Author(s): Miller David G
Mar/Apr 2017 Pg. 95-102	U.S. Food and Drug Administration Inspections: Guide to a Successful Outcome for 503A Sterile Compounding Pharmacies Author(s): Yoch Doug
Nov/Dec 2016 Pg. 457-458	U.S. Food and Drug Administration List of Drugs NOT to be Used in Compounded Medications for Humans (The Negative List) Author(s):
Sep/Oct 2014 Pg. 379-380	Final Guidance for Pharmacy Compounding of Human Drug Products Under Section 503A Author(s): Blankenship Cynthia E
Jul/Aug 2022 Pg. 298-301	The Role of Compounding Pharmacists During Drug Shortages Author(s): Ofei Kelvin
Sep/Oct 2021 Pg. 358-362	Determining Whether a Substance is Legal to Compound with Under Section 503A of the FDCA Author(s): Cabaleiro Joe
Jul/Aug 2012 Pg. 294-298	Drug Shortages & Discontinued Drugs: The Effects on Patients and Healthcare Providers Author(s): Allen Loyd V Jr, Williams LaVonn A
Sep/Oct 2015 Pg. 389-390	Nominations of Difficult to Compound Drugs to the U.S. Food and Drug Administration--Pharmacy Compounding Advisory Committee: Part 1 Author(s): Allen Loyd V Jr
Jul/Aug 2020 Pg. 296-297	Finally: A Final U.S. Food and Drug Administration Memorandum of Understanding, but It's Flawed Author(s): Brunner Scott
Jan/Feb 2019 Pg. 32-33	U.S. Food and Drug Administration Inspection Authority: How to Know Whether U.S. Food and Drug Administration Inspectors Are Crossing the Line Author(s): Snow Stephen T, Stannard Robert W, Bellis Jennifer, Moss Carrie A
Nov/Dec 2012 Pg. 456-460	Drug Shortage Compounding: The Only Safe Medication Source in a Time of Crisis Author(s): Lyon Joanna
Mar/Apr 2011 Pg. 92	PreScription: Discontinued Drugs and Drug Shortages Author(s): Allen Loyd V Jr
May/Jun 2014 Pg. 208	The U.S. Food and Drug Administration Responds to the International Academy of Compounding Pharmacists' Outsourcing Letter Author(s): Miller David G
Jan/Feb 2023 Pg. 22-23	The U.S. Food and Drug Administration Takes Aim at Compounded Thyroid Hormone Author(s): Brunner Scott